Depo-Medrol® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Depo-Medrol®

Active ingredient

Methylprednisolone Acetate

Application type

NADA

Sponsor

Zoetis Inc.

Applications on record

1

First published

December 7, 2021

Adverse event reports

Source: openFDA VeDDRA

2,267

Reports mentioning this ingredient

May 29, 1987 – March 22, 2026

711

Classified serious

per reporter assessment

327

Lack of expected efficacy

resistance signal

8

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “METHYLPREDNISOLONE ACETATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Vomiting	175
Death	174
Anorexia	169
INEFFECTIVE, ANTIINFLAMMATORY	118
Depression	117
Lack of efficacy - NOS	108
Lethargy (see also Central nervous system depression in 'Neurological')	102
Weight loss	99
Death by euthanasia	97
Hyperglycaemia	94
Dyspnoea	81
Polydipsia	76
Suspension, Abnormal	73
Ataxia	67
Fever	67
Elevated alanine aminotransferase (ALT)	66
Abnormal radiograph finding	64
Polyuria	61
Diarrhoea	58
Anaphylaxis	54

Species affected

Source: openFDA VeDDRA

Cat 1,450 Dog 547 Horse 98 Other 5 Human 2 Pig 1 Sheep 1 Goat 1 Cattle 1 Rabbit 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient